BFM
ACET icon

Boothbay Fund Management’s Adicet Bio ACET Stock Holding History

Boothbay Fund Management’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-895
Closed -$209K – 2198
2022
Q2 		$209K Sell
895
-2,275
-72% -$500K 0.01% 1710
2022
Q1 		$1.01M Hold
3,170
– – 0.02% 893
2021
Q4 		$887K Buy
3,170
+730
+30% +$125K 0.02% 812
2021
Q3 		$306K Buy
2,440
+171
+8% +$21.2K 0.01% 1319
2021
Q2 		$120K Sell
2,269
-371
-14% -$75.6K ﹤0.01% 1705
2021
Q1 		$230K Buy
2,640
+1,060
+67% +$243K 0.01% 1306
2020
Q4 		$355K Buy
1,580
+37
+2% +$7.58K 0.01% 883
2020
Q3 		$293K Buy
1,543
+481
+45% +$122K 0.02% 813
2020
Q2 		$256K Buy
+1,062
New +$209K 0.02% 740
2019
Q3 		– Sell
-231
Closed -$264K – 749
2019
Q2 		$264K Buy
+231
New +$209K 0.02% 555

Other funds holding ACET

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Boothbay Fund Management's ACET Position: Q3 2022 in Review

Boothbay Fund Management sold out of Adicet Bio (ACET) in Q3 2022, closing a stake of 895 shares — an estimated $209K sold.

Boothbay Fund Management first reported a position in ACET in Q2 2019 and held it in 10 quarters. The position peaked at $1.01M in Q1 2022. 102 funds tracked by Wall St. Rank hold ACET as of Q3 2022.

  • Boothbay Fund Management reported no remaining Adicet Bio position as of Q3 2022 after selling out during the quarter.
  • Boothbay Fund Management sold 895 Adicet Bio shares in Q3 2022, an estimated $209K.
  • Boothbay Fund Management first reported a position in Adicet Bio in Q2 2019 and held it in 10 quarters.
  • Boothbay Fund Management's Adicet Bio position peaked at $1.01M in Q1 2022.
  • 102 funds tracked by Wall St. Rank held Adicet Bio as of Q3 2022.

Based on Boothbay Fund Management's 13F filing for Q3 2022, filed 14 Nov 2022.